Literature DB >> 2564566

Induction of graft-versus-host disease after autologous bone marrow transplantation.

R J Jones1, G B Vogelsang, A D Hess, E R Farmer, R B Mann, R B Geller, S Piantadosi, G W Santos.   

Abstract

To induce graft-versus-host disease (GvHD) in patients undergoing autologous bone marrow transplantation (BMT), five consecutive patients with non-Hodgkin lymphoma or Hodgkin's disease in resistant relapse were treated with cyclophosphamide and total body irradiation or busulphan and cyclophosphamide, followed by autologous BMT. The patients received cyclosporin 1 mg/kg per day intravenously for 28 days after BMT. Histologically proven grade II acute GvHD of the skin developed in all the patients at a median of 11 days (range 9-13) after BMT. One patient died and the GvHD resolved in 1-3 weeks in the four remaining patients--spontaneously in two and with corticosteroid treatment in two. Lymphocytes from one patient obtained at the time of GvHD were cytotoxic for the patient's own pretransplant lymphocytes. Cytotoxicity was blocked by antibodies directed against class II histocompatibility (HLA-DR or Ia) antigens. Cyclosporin-induced GvHD after autologous BMT resembles mild GvHD after allogeneic grafting. This syndrome appears to be mediated by autoreactive Ia-specific lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564566     DOI: 10.1016/s0140-6736(89)92575-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 2.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 3.  Autologous graft-versus-host disease.

Authors:  M J Kennedy; A D Hess
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?

Authors:  N El-Jurdi; M Ueda; L Jia; H Lazarus
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

5.  Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Authors:  Andrea Schietinger; Jeffrey J Delrow; Ryan S Basom; Joseph N Blattman; Philip D Greenberg
Journal:  Science       Date:  2012-01-19       Impact factor: 47.728

Review 6.  Xenobiotics, chimerism and the induction of tolerance following organ transplantation.

Authors:  C P Delaney; A W Thomson; A J Demetris; T E Starzl
Journal:  Ther Immunol       Date:  1994-06

Review 7.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

Review 8.  Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation.

Authors:  M J Kennedy; R J Jones
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.

Authors:  N R Sinclair
Journal:  CMAJ       Date:  1992-09-01       Impact factor: 8.262

Review 10.  Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach.

Authors:  Robert Frank Cornell; Parameswaran Hari; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.